Look I have the feeling that Invion 103 has just lacked some love. The big more immediate prize is with our respiratory drugs. Yesterdays announcement IMO was quite inadequate. It was the first bit of news since September 8 last year where the company said they 'look forward to leveraging this understanding into the final cohorts of the study, which include significantly higher dosages in patients with more severe disease'. What has happened to all the talk around Lupus nephritis? These patients with class 1 and 2 kidney disease were recruited??? The drug suppressed nephritis in mice studies. 2 year trial for 28 patients, 2 announcements...... a real shame, this novel drug needs to get to market.
IVX Price at posting:
2.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)